Larry Hsu Sample Contracts

SEC Documents
Filings
Personal financials
Insider transactions
Previous Companies
director, officer: President and CEO until September 18th, 2013
Impax Laboratories Inc – EMPLOYMENT AGREEMENT (January 14th, 2010)

EMPLOYMENT AGREEMENT (“Agreement”), entered into as of January 1, 2010 (the “Effective Date”), by and between Impax Laboratories, Inc., a Delaware corporation (the “Company”), and Larry Hsu, Ph.D. (the “Executive”).

Impax Laboratories Inc – AMENDMENT NO. 1, DATED MAY 19, 2009, TO EMPLOYMENT AGREEMENT, DATED DECEMBER 14, 1999, BY AND BETWEEN IMPAX LABORATORIES, INC. AND LARRY HSU, PH.D. (August 5th, 2009)
Impax Laboratories Inc – EMPLOYMENT AGREEMENT (December 2nd, 2008)

This Employment Agreement, effective as of this 14th day of December, 1999 (the “Effective Date”), is by and among IMPAX LABORATORIES, INC., a Delaware corporation, with a business address at 30831 Huntwood Ave., Hayward, California 94544 (the “Company”) and Larry Hsu, Ph.D., with a mailing address at 30831 Huntwood Avenue, Hayward, California 94544 (“Executive”).

Impax Laboratories Inc – EMPLOYMENT AGREEMENT (October 10th, 2008)

This Employment Agreement, effective as of this                      day of                     , 1999 (the “Effective Date”), is by and among IMPAX LABORATORIES, INC., a Delaware corporation, with a business address at 30831 Huntwood Ave., Hayward, California 94544 (the “Company”) and Larry Hsu, Ph.D., with a mailing address at 30831 Huntwood Avenue, Hayward, California 94544 (“Executive”).

Impax Laboratories Inc – IMPAX Reports SEC Actions HAYWARD, Calif.–(BUSINESS WIRE)–Jan. 2, 2007–IMPAX Laboratories, Inc. (OTC:IPXL) ("IMPAX" or the "Company") reported that on Friday December 29, 2006, the Securities and Exchange Commission ("SEC") issued an order instituting an administrative proceeding to determine whether, in light of the Company's failure to file reports since September 2004, the registration of its securities under Section 12 of the Securities Exchange Act of 1934 should be suspended or revoked. An Administrative Law Judge will consider the evidence in this matter and is ordered to issue an initi (January 8th, 2007)

HAYWARD, Calif.–(BUSINESS WIRE)–Jan. 2, 2007–IMPAX Laboratories, Inc. (OTC:IPXL) ("IMPAX" or the "Company") reported that on Friday December 29, 2006, the Securities and Exchange Commission ("SEC") issued an order instituting an administrative proceeding to determine whether, in light of the Company's failure to file reports since September 2004, the registration of its securities under Section 12 of the Securities Exchange Act of 1934 should be suspended or revoked. An Administrative Law Judge will consider the evidence in this matter and is ordered to issue an initial decision within 120 days. Also on December 29, 2006, the SEC suspended trading in IMPAX shares during the 10-business-day period from December 29, 2006 through January 16, 2007 because of the Company's failure to file reports.The Company has not filed a periodic report since its report for the period ended September 30, 2004 because, as it announced in May 2005, it has been working to determine the appropriate accountin

Impax Laboratories Inc – IMPAX SIGNS EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENT WITH (November 8th, 2005)
Impax Laboratories Inc – IMPAX RECEIVES NOTICE OF DELISTING FROM NASDAQ (August 5th, 2005)
Impax Laboratories Inc – IMPAX RECEIVES NOTICE OF ADDITIONAL (May 23rd, 2005)
Impax Laboratories Inc – IMPAX RECEIVES NOTICE OF POSSIBLE DELISTING FOR FAILURE TO FILE FORM 10-K (April 7th, 2005)
Impax Laboratories Inc – PRESS RELEASES (April 4th, 2005)
Impax Laboratories Inc – Company Contacts: Investor Relations Contacts: (September 1st, 2004)

HAYWARD, Calif. (September 1, 2004) – IMPAX Laboratories, Inc. (NASDAQ NM: IPXL) today announced that the District Court of Wilmington, Delaware has ruled that Aventis Pharmaceutical’s patent 5,527,814 related to the use of Rilutek® for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is valid, enforceable and infringed by IMPAX’s proposed generic product. IMPAX had filed a declaratory judgment action seeking a judicial declaration of invalidity, unenforceability and non-infringement regarding this patent. According to NDCHealth, U.S. sales of Rilutek were $35 million in the 12 months ended June 30, 2004.

Impax Laboratories Inc – IMPAX signs Distribution Agreements with Leiner Health Products, LLC for Loratadine Products (July 13th, 2004)

Company Contacts: IMPAX Laboratories, Inc. Barry R. Edwards, CEO (215) 933-0323 Ext. 4360 Larry Hsu, Ph.D. President (510) 476-2000 Ext. 1111 Cornel C. Spiegler, CFO (215) 289-2220 Ext. 1706 www.impaxlabs.com Investor Relations Contacts: Lippert/Heilshorn & Associates, Inc. Kim Sutton Golodetz (kgolodetz@lhai.com) (212) 838-3777 Bruce Voss (bvoss@lhai.com) (310) 691-7100 www.lhai.com

Impax Laboratories Inc – Company Contacts: Investor Relations Contacts: (October 28th, 2003)

HAYWARD, Calif. (October 27, 2003) – IMPAX Laboratories, Inc. (NASDAQ NM: IPXL) today announced that it has entered into a settlement and license agreement with Schering-Plough Corporation (NYSE: SGP) related to IMPAX’s generic version of Claritin-D® 24-Hour (Loratadine and Pseudoephedrine Sulfate, 10mg/240mg) Extended Release Tablets. This agreement resolves all of the outstanding patent litigation between the parties on this product. The financial terms of the settlement and license, which remain undisclosed, are not material to IMPAX's financial position or results of operations.

Impax Laboratories Inc – IMPAX SIGNS AGREEMENT WITH ANDRX AND TEVA FOR GENERIC (July 31st, 2003)
Impax Laboratories Inc – EMPLOYMENT AGREEMENT (March 30th, 2000)
Impax Laboratories Inc – EMPLOYMENT AGREEMENT (March 30th, 2000)
Impax Laboratories Inc – EMPLOYMENT AGREEMENT (March 30th, 2000)
Global Pharmaceutical Corp \De\ – STOCKHOLDERS' AGREEMENT (December 27th, 1999)
Global Pharmaceutical Corp \De\ – EMPLOYMENT AGREEMENT (November 9th, 1999)
Global Pharmaceutical Corp \De\ – EMPLOYMENT AGREEMENT (November 9th, 1999)
Global Pharmaceutical Corp \De\ – EMPLOYMENT AGREEMENT (November 9th, 1999)
Global Pharmaceutical Corp \De\ – News Release (August 2nd, 1999)